美国目前和未来的长期COVID负担(美国)

Sarah M Bartsch, Kevin L Chin, Ulrich Strych, Danielle C John, Tej D Shah, Maria Elena Bottazzi, Kelly J O’Shea, McKaylee Robertson, Colleen Weatherwax, Jessie Heneghan, Marie F Martinez, Allan Ciciriello, Sarah Kulkarni, Kavya Velmurugan, Alexis Dibbs, Sheryl A Scannell, Yanhan Shen, Denis Nash, Peter J Hotez, Bruce Y Lee
{"title":"美国目前和未来的长期COVID负担(美国)","authors":"Sarah M Bartsch, Kevin L Chin, Ulrich Strych, Danielle C John, Tej D Shah, Maria Elena Bottazzi, Kelly J O’Shea, McKaylee Robertson, Colleen Weatherwax, Jessie Heneghan, Marie F Martinez, Allan Ciciriello, Sarah Kulkarni, Kavya Velmurugan, Alexis Dibbs, Sheryl A Scannell, Yanhan Shen, Denis Nash, Peter J Hotez, Bruce Y Lee","doi":"10.1093/infdis/jiaf030","DOIUrl":null,"url":null,"abstract":"Background Long COVID, which affects an estimated 44.69-48.04 million people in the U.S., is an ongoing public health concern that will continue to grow as SARS-CoV-2 continues to spread. Methods We developed a computational simulation model representing the clinical course, the health effects, and the associated costs of a person with Long COVID. Results Simulations show that the average total cost of a Long COVID case can range from $5,084-$11,646 (assuming symptoms only last 1 year) with 92.5%-95.2% of these costs being productivity losses. Therefore, the current number of Long COVID cases could end up costing society at least $2.01-$6.56 billion, employers at least $1.99-$6.49 billion in productivity losses, and third-party payers $21-68.5 million annually (6%-20% probability of developing Long COVID). These cases would accrue 35,808-121,259 QALYs lost and 13,484-45,468 DALYs. Moreover, each year, there may be an additional $698.5 million in total costs, 14,685 QALYs lost, and 5,628 DALYs, if the incidence of COVID is 100 per 10,000 persons (similar to that seen in 2023). Every 10-point increase in COVID incidence results in an additional $365 million in total costs, 5,070 QALYs lost, and 1,900 DALYs each year. Conclusion The current health and economic burden of Long COVID may already exceed that of a number of other chronic disease and will continue to grow each year as there are more and more COVID-19 cases. This could be a significant drain on businesses, third party payers, the healthcare system, and all of society.","PeriodicalId":501010,"journal":{"name":"The Journal of Infectious Diseases","volume":"50 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2025-01-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"The Current and Future Burden of Long COVID in the United States (U.S.)\",\"authors\":\"Sarah M Bartsch, Kevin L Chin, Ulrich Strych, Danielle C John, Tej D Shah, Maria Elena Bottazzi, Kelly J O’Shea, McKaylee Robertson, Colleen Weatherwax, Jessie Heneghan, Marie F Martinez, Allan Ciciriello, Sarah Kulkarni, Kavya Velmurugan, Alexis Dibbs, Sheryl A Scannell, Yanhan Shen, Denis Nash, Peter J Hotez, Bruce Y Lee\",\"doi\":\"10.1093/infdis/jiaf030\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Background Long COVID, which affects an estimated 44.69-48.04 million people in the U.S., is an ongoing public health concern that will continue to grow as SARS-CoV-2 continues to spread. Methods We developed a computational simulation model representing the clinical course, the health effects, and the associated costs of a person with Long COVID. Results Simulations show that the average total cost of a Long COVID case can range from $5,084-$11,646 (assuming symptoms only last 1 year) with 92.5%-95.2% of these costs being productivity losses. Therefore, the current number of Long COVID cases could end up costing society at least $2.01-$6.56 billion, employers at least $1.99-$6.49 billion in productivity losses, and third-party payers $21-68.5 million annually (6%-20% probability of developing Long COVID). These cases would accrue 35,808-121,259 QALYs lost and 13,484-45,468 DALYs. Moreover, each year, there may be an additional $698.5 million in total costs, 14,685 QALYs lost, and 5,628 DALYs, if the incidence of COVID is 100 per 10,000 persons (similar to that seen in 2023). Every 10-point increase in COVID incidence results in an additional $365 million in total costs, 5,070 QALYs lost, and 1,900 DALYs each year. Conclusion The current health and economic burden of Long COVID may already exceed that of a number of other chronic disease and will continue to grow each year as there are more and more COVID-19 cases. This could be a significant drain on businesses, third party payers, the healthcare system, and all of society.\",\"PeriodicalId\":501010,\"journal\":{\"name\":\"The Journal of Infectious Diseases\",\"volume\":\"50 1\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2025-01-23\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"The Journal of Infectious Diseases\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1093/infdis/jiaf030\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"The Journal of Infectious Diseases","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1093/infdis/jiaf030","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

摘要

据估计,新冠肺炎在美国影响了4469万至4804万人,是一个持续存在的公共卫生问题,随着SARS-CoV-2的继续传播,这一问题将继续加剧。方法建立了一个计算模拟模型,代表长COVID患者的临床病程、健康影响和相关成本。模拟显示,长期COVID病例的平均总成本可能在5084美元至11646美元之间(假设症状只持续1年),其中92.5%至95.2%的成本是生产力损失。因此,目前的长冠肺炎病例数量最终可能导致社会损失至少20.1亿至65.6亿美元,雇主生产力损失至少19.9亿至64.9亿美元,第三方支付者每年损失26850万美元(发生长冠肺炎的概率为6%-20%)。这些案件将累计损失35,808-121,259个QALYs和13,484-45,468个DALYs。此外,如果新冠肺炎的发病率为每万人100例(与2023年类似),每年可能会增加6.985亿美元的总成本,损失14,685个质量年数和5,628个伤残调整年。新冠肺炎发病率每增加10个百分点,总成本就会增加3.65亿美元,每年损失5070个生命质量年和1900个伤残调整生命年。结论长冠状病毒病目前的健康和经济负担可能已经超过了许多其他慢性疾病,并且随着COVID-19病例的越来越多,这种负担将每年继续增加。这可能会对企业、第三方付款人、医疗保健系统和整个社会造成重大损失。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
The Current and Future Burden of Long COVID in the United States (U.S.)
Background Long COVID, which affects an estimated 44.69-48.04 million people in the U.S., is an ongoing public health concern that will continue to grow as SARS-CoV-2 continues to spread. Methods We developed a computational simulation model representing the clinical course, the health effects, and the associated costs of a person with Long COVID. Results Simulations show that the average total cost of a Long COVID case can range from $5,084-$11,646 (assuming symptoms only last 1 year) with 92.5%-95.2% of these costs being productivity losses. Therefore, the current number of Long COVID cases could end up costing society at least $2.01-$6.56 billion, employers at least $1.99-$6.49 billion in productivity losses, and third-party payers $21-68.5 million annually (6%-20% probability of developing Long COVID). These cases would accrue 35,808-121,259 QALYs lost and 13,484-45,468 DALYs. Moreover, each year, there may be an additional $698.5 million in total costs, 14,685 QALYs lost, and 5,628 DALYs, if the incidence of COVID is 100 per 10,000 persons (similar to that seen in 2023). Every 10-point increase in COVID incidence results in an additional $365 million in total costs, 5,070 QALYs lost, and 1,900 DALYs each year. Conclusion The current health and economic burden of Long COVID may already exceed that of a number of other chronic disease and will continue to grow each year as there are more and more COVID-19 cases. This could be a significant drain on businesses, third party payers, the healthcare system, and all of society.
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
Decreased persistence of maternal antibodies in infants who are HIV-exposed and uninfected. Diagnostic Methods for Cryptosporidiosis in Low- and Middle-Income Countries: A Systematic Narrative Review. High Nasopharyngeal SARS-CoV-2 Load and Delayed Clearance in Hospitalized Patients With Blood Autoantibodies Neutralizing Type I Interferons. Investigation of correlates of protection against gonococcal infection by comparative immunoprofiling of responses in experimental and clinical studies. Schistosoma mansoni Infections Are Associated With Fecal Calprotectin Markers of Gut Inflammation After Accounting for HIV, Hepatitis B, and Malaria.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1